EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Plasma Glycoprotein Milieu in the Hemato-Oncological Patient Inhibits Platelet Function

Iris M De Cuyper iD, Graciela Carbajo-Argüelles iD, María Villa-Fajardo, Andrea Acebes-Huerta iD, Rutger A Middelburg iD, Johannes A Eble iD, Dick H W Dekkers iD, Jeroen A A Demmers, Jean-Louis H Kerkhoffs, Jaap Jan Zwaginga iD, Laura Gutiérrez iD

Biomolecules · 22.05.2026 · 16 (6) · 761

DOI: 10.3390/biom16060761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 22.05.2026. Verfasst von Iris M De Cuyper und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sanquin Blood Supply Foundation, Department Research, 1066 CX Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Blood Platelets, Leukemia, Myeloid, Acute, Thrombocytopenia, Glycoproteins. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Economía y Competitividad, Ministerio de Ciencia, Innovación y Universidades, Instituto de salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemato-oncological patients with chemotherapy-induced thrombocytopenia are a major recipient group of frequent platelet (PLT) transfusion. Prophylactic platelet transfusions are administered when platelet counts fall below 10 × 109 PLT/L, to prevent severe or fatal bleeding. However, these prophylactic platelet transfusions do not always result in the prevention of bleeding. Pre- or post-transfusion acquired dysfunction of donor platelets in this respect could play a role. We previously reported intrinsic and transfusion-dependent platelet alterations in hemato-oncological patients. In particular, the expression of relevant platelet receptors was affected in donor platelets after incubation with patient’s plasma, which could explain, at least in part, the variable efficacy of platelet transfusions in these patients. In the present manuscript we show that plasma from acute myeloid leukemia (AML) patients undergoing chemotherapy inhibits functionality of allogenic platelets. Further proteomic analysis allowed us to observe alterations in the composition of plasma samples, and to identify key plasma components which could be responsible for platelet function inhibition and explain bleeding in patients notwithstanding platelet transfusions. We anticipate that with the obtained results, platelet transfusion support can be further personalized in patients receiving chemotherapy and applications might expand to maximize the clinical efficacy of procedures such as bone marrow transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsLeukemia, Myeloid, AcuteThrombocytopeniaGlycoproteinsHumansPlatelet TransfusionFemaleMaleMiddle AgedProteomicsAdult

Stichwörter der Autor:innen

chemotherapyhemato-oncological patientsplasma factorsplatelet functionplatelet transfusionvWF

Substanzen

Glycoproteins

Autor:innen und Institutionen

  • Sanquin Blood Supply Foundation, Department Research, 1066 CX Amsterdam, The Netherlands.
  • Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
  • Department of Hematology, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain.
  • Center for Clinical Transfusion Research, Sanquin Blood Supply Foundation, 2333 ZA Leiden, The Netherlands.
  • Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, 48149 Münster, Germany.
  • Center for Proteomics, Erasmus University Medical Center (Erasmus MC), 3015 CN Rotterdam, The Netherlands.

ORCID-Profile: Iris M De Cuyper, Graciela Carbajo-Argüelles, Andrea Acebes-Huerta, Rutger A Middelburg, Johannes A Eble, Dick H W Dekkers, Jaap Jan Zwaginga, Laura Gutiérrez

Förderung

  • Ministerio de Economía y Competitividad
  • Ministerio de Ciencia, Innovación y Universidades
  • Instituto de salud Carlos III
  • Deutsche Forschungsgemeinschaft
  • Instituto de Investigación Sanitaria del Principado de Asturias
  • Sanquin Blood Supply Foundation
  • Consorcio Centro de Investigación Biomédica en Red de Salud Mental
  • 2024 Industrial Doctorate Contract

Zitieren

APA

De Cuyper, I. M., Carbajo-Argüelles, G., Villa-Fajardo, M., Acebes-Huerta, A., Middelburg, R. A., Eble, J. A., Dekkers, D. H. W., Demmers, J. A. A., Kerkhoffs, J. H., Zwaginga, J. J., & Gutiérrez, L. (2026). The Plasma Glycoprotein Milieu in the Hemato-Oncological Patient Inhibits Platelet Function. Biomolecules, 16(6), 761. https://doi.org/10.3390/biom16060761

Vancouver

De Cuyper IM, Carbajo-Argüelles G, Villa-Fajardo M, Acebes-Huerta A, Middelburg RA, Eble JA, et al. The Plasma Glycoprotein Milieu in the Hemato-Oncological Patient Inhibits Platelet Function. Biomolecules. 2026;16(6):761. doi:10.3390/biom16060761

BibTeX
@article{DeCuyper2026,
  author = {De Cuyper, Iris M and Carbajo-Argüelles, Graciela and Villa-Fajardo, María and Acebes-Huerta, Andrea and Middelburg, Rutger A and Eble, Johannes A and Dekkers, Dick H W and Demmers, Jeroen A A and Kerkhoffs, Jean-Louis H and Zwaginga, Jaap Jan and Gutiérrez, Laura},
  title = {The Plasma Glycoprotein Milieu in the Hemato-Oncological Patient Inhibits Platelet Function},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {761},
  doi = {10.3390/biom16060761}
}
Kostenlos starten →